BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 35390430)

  • 1. HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect.
    Foo CS; Abdelnabi R; Kaptein SJF; Zhang X; Ter Horst S; Mols R; Delang L; Rocha-Pereira J; Coelmont L; Leyssen P; Dallmeier K; Vergote V; Heylen E; Vangeel L; Chatterjee AK; Annaert PP; Augustijns PF; De Jonghe S; Jochmans D; Gouwy M; Cambier S; Vandooren J; Proost P; van Laer C; Weynand B; Neyts J
    Antiviral Res; 2022 Jun; 202():105311. PubMed ID: 35390430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
    N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
    J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the coronavirus SARS-CoV-2: computational insights into the mechanism of action of the protease inhibitors lopinavir, ritonavir and nelfinavir.
    Bolcato G; Bissaro M; Pavan M; Sturlese M; Moro S
    Sci Rep; 2020 Dec; 10(1):20927. PubMed ID: 33262359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
    Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
    J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.
    De Luca M; Miccinesi G; Chiappini E; Zappa M; Galli L; De Martino M
    Int J Immunopathol Pharmacol; 2005; 18(4):729-35. PubMed ID: 16388722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
    Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term responses to treatment including ritonavir or nelfinavir in HIV-1-infected children. Pediatric AIDS Group of Switzerland.
    Nadal D; Steiner F; Cheseaux JJ; Lazarevitch CA; Aebi C; Kind C; Rudin C
    Infection; 2000 Sep; 28(5):287-96. PubMed ID: 11073135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.
    Sulkowski MS; Mehta SH; Chaisson RE; Thomas DL; Moore RD
    AIDS; 2004 Nov; 18(17):2277-84. PubMed ID: 15577540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-treatment With HIV Protease Inhibitor Nelfinavir Greatly Increases Late-phase Apoptosis of Drug-resistant KBV20C Cancer Cells Independently of P-Glycoprotein Inhibition.
    Kim JY; Park YJ; Lee BM; Yoon S
    Anticancer Res; 2019 Jul; 39(7):3757-3765. PubMed ID: 31262902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.
    Lafeuillade A; Solas C; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
    HIV Clin Trials; 2002; 3(1):27-35. PubMed ID: 11819183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus.
    Yamamoto N; Yang R; Yoshinaka Y; Amari S; Nakano T; Cinatl J; Rabenau H; Doerr HW; Hunsmann G; Otaka A; Tamamura H; Fujii N; Yamamoto N
    Biochem Biophys Res Commun; 2004 Jun; 318(3):719-25. PubMed ID: 15144898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir.
    Bates DE; Herman RJ
    Ann Pharmacother; 2006 Jun; 40(6):1190-5. PubMed ID: 16720703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir.
    Tebas P; Patick AK; Kane EM; Klebert MK; Simpson JH; Erice A; Powderly WG; Henry K
    AIDS; 1999 Feb; 13(2):F23-8. PubMed ID: 10202820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Darunavir: a review of its use in the management of HIV infection in adults.
    McKeage K; Perry CM; Keam SJ
    Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir.
    King MS; Brun SC; Kempf DJ
    J Infect Dis; 2005 Jun; 191(12):2046-52. PubMed ID: 15897990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Antiviral Efficacy of Viral Protease Inhibitors against the Novel SARS-CoV-2 In Vitro.
    Zhang L; Liu J; Cao R; Xu M; Wu Y; Shang W; Wang X; Zhang H; Jiang X; Sun Y; Hu H; Li Y; Zou G; Zhang M; Zhao L; Li W; Guo X; Zhuang X; Yang XL; Shi ZL; Deng F; Hu Z; Xiao G; Wang M; Zhong W
    Virol Sin; 2020 Dec; 35(6):776-784. PubMed ID: 32910347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.